KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Receivables (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Change in Receivables for 8 consecutive years, with -$6.3 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 915.6% to -$6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.9 million through Dec 2025, down 154.39% year-over-year, with the annual reading at -$6.9 million for FY2025, 154.39% down from the prior year.
  • Change in Receivables hit -$6.3 million in Q4 2025 for Castle Biosciences, down from -$1.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $5.8 million in Q3 2023 to a low of -$6.3 million in Q4 2025.
  • Historically, Change in Receivables has averaged $1.6 million across 5 years, with a median of $2.1 million in 2021.
  • Biggest five-year swings in Change in Receivables: surged 11502.0% in 2023 and later crashed 915.6% in 2025.
  • Year by year, Change in Receivables stood at -$1.5 million in 2021, then soared by 137.09% to $540000.0 in 2022, then skyrocketed by 113.15% to $1.2 million in 2023, then plummeted by 33.19% to $769000.0 in 2024, then plummeted by 915.6% to -$6.3 million in 2025.
  • Business Quant data shows Change in Receivables for CSTL at -$6.3 million in Q4 2025, -$1.9 million in Q3 2025, and -$3.9 million in Q2 2025.